Interest in transdermal drug delivery has increased in recent years owing to its many advantages over other routes of administration. In order to evaluate a transdermal product effectively, three main issues need to be addressed: (1) the kind of skin model that will be used to evaluate the drug permeation; (2) the mathematical model that will be used to characterize the permeation of the drug across the skin; and (3) the diffusion apparatus that will be used to conduct the permeation study.
Immobilized artificial-membrane chromatography is a potential in vitro technique for determining lipophilicity and studying drug transport and membrane interactions. It is reproducible, efficient and simple. Several other and newer applications of immobilized stationary-phase liquid chromatography have been reported, including the purification of membrane proteins, the synthesis of biomolecules and the simultaneous determination of enzyme activity and enantioselectivity. This article describes the immobilized artificial-membrane concept and provides an overview of the applications, advantages and limitations, in general, of immobilized stationary-phase chromatography.
“The barriers between ‘silos’ in pharmaceutical R&D workflows are slowly eroding and this is driving a wider exchange of information across the various R&D disciplines.”
Vehicles designed to enhance drug delivery through the skin must incorporate specific elements that improve the ability of the delivery system to overcome the barrier posed by the stratum corneum. This review discusses several chemical penetration enhancers that have been investigated as potential tools to increase drug flux. In addition, lipid-based delivery systems offer an attractive alternative to traditional drug vehicles. The relationship between liposome composition and drug permeation is discussed, in addition to the possible mechanism of action of lipid vesicle-mediated drug delivery.
An arsenic compound, previously used as an insecticide, is set to become the latest addition to the armoury for treating a rare form of leukaemia. On 26 September 2000, the FDA announced the approval of Trisenox (arsenic trioxide) for the treatment of acute promyelocytic leukaemia (APL), which affects approximately 2000 people each year in the USA.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：